Sambrinvest
Sambrinvest S.A. is a private equity and venture capital firm specializing in direct and fund of funds investments. Within direct investments, it focuses on startup, spin-out, spin-off, growth capital and turnaround investments. It does not invest in the retail, hospitality or banking and insurance industries. It invests in the following sectors: Agri-Food, audiovisual, gaming, automotive, biotechnology, pharmaceuticals, wholesale, construction, digital, environmental, alternative energy, manufacturing, computing, electronics, services, services to people, tourism, transportation, logistics and real estate. The firm is also open for investments in other sectors. The firm seeks to invest in small and medium sized companies in the Charleroi Sud-Hainaut and Thuin districts of Belgium. It invests in the form of a minority stake, subordinated loan or participating capital loan, subscription to a bond issue, unsecured loan or repayable advance, and participation in the acquisition of industrial property rights. It typically invests at most €1.25 million ($1.70 million) in companies with a turnover below €50 million ($68 million). Sambrinvest S.A. was founded on January 9, 1985 and is based in Gosselies, Belgium.
Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacturing of satellites equipped with advanced sensors. The company focuses on addressing complex challenges in the aerospace sector by employing innovative approaches. In addition to satellite technology, Aerospacelab also creates tools that leverage artificial intelligence and machine learning to automate various tasks, enhancing operational efficiency and capabilities in space exploration and data collection.
Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.
HeartKinetics is a developer of a smart wireless connected device to provide a measure of cardiac contractility together with the traditional electrocardiogram.
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.
HireRing is the on-demand staffing platform connecting employers with top professional recruiters per vacancy request, and for the hiring fee they set upfront. Their platform makes it fast and easy for employers to submit their hiring needs to the adequate recruitment agencies, and for agencies to choose the adequate business opportunities to work on.
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketing success. Start your search now on www.sortlist.com
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
We bring simplicity in the management of staff schedules. Shyfter is a web and app-based platform to facilitate day to day management problems related to staff scheduling. Our role is firstly to make it easier to connect employers and employees through a single and intuitive platform and secondly to eliminate a whole series of administrative and legal problems related to staff scheduling.
ExeVir Bio BV is a Belgium-based biotechnology company established in 2020, focused on developing single-domain antibody therapies to combat viral infections. The company utilizes a llama-derived antibody technology platform, specifically the VHH technology, to create robust antiviral treatments that offer broad protection against coronaviruses, including SARS-CoV-2. ExeVir's lead candidate, VHH72-FC, targets a conserved region on the virus's spike protein essential for cellular entry. This innovative approach not only aims to provide effective treatment and prevention strategies for viral infections but also enables rapid development of drug candidates in response to emerging health threats, ensuring stability and cost-effectiveness for global access. ExeVir Bio's therapies are designed to reduce viral load and inflammation, thereby supporting immune responses and protecting vulnerable populations, including healthcare workers and individuals with co-morbidities.
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.
Utopix Pictures SA, founded in 2015 and based in Mont-Saint-Guibert, Belgium, operates a platform designed to connect clients with professionals in the photography, film, and image industries. The company focuses on simplifying the process of finding the ideal photographer or videographer to bring business projects to life. Utopix Pictures understands the importance of visual content and aims to facilitate seamless collaboration between clients and creative professionals, ensuring that ideas are effectively transformed into compelling images.
Cognivia is a company specializing in the development of analytical tools aimed at enhancing the clinical development of new medicines. Founded in 2013 and headquartered in Gosselies, Belgium, Cognivia focuses on optimizing therapeutic drug development programs. Its flagship product, Placebell, improves test sensitivity by characterizing and managing the individual placebo response in various disease states, where this response can obscure the efficacy of important therapies. The company employs an academic approach to commercialize its technology, drawing on the extensive expertise of its founders and a professional network of advisors. Cognivia’s mission is to improve patient quality of life by assisting healthcare providers and pharmaceutical companies in identifying the most effective therapies for individual patients, while actively involving patients as critical stakeholders in the development process.
Smartbeam is a construction-tech startup solving construction problems with technology solutions. We are developing a budget management application for construction that helps every site stakeholders (general contractors, subcontractors, architects and developers) to work together from the tendering phase to the end of the project. Our team is made of Construction, Business and Software Engineers and we are currently working with experienced construction partners to co-develop the software and create a modern vision of construction budget management 2.0.
With Commuty, they save money while reducing constraints and increasing flexibility. Smart parking management organises company managed parking spots allocationsand bookings according to their parking policy. Bicycle raising connects cyclers with similar routes, organises the use of shared bicycles and automates kilometer refund. Ride sharing elevation connects riders, automates ride sharing tax advantage and organises guaranteed return.
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketing success. Start your search now on www.sortlist.com
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.
Opinum, based in Braine l'Alleud, Belgium, specializes in providing innovative hardware technologies and has developed the "Opinum Data Hub" platform. This platform supports energy and environmental stakeholders in their digital transformation efforts by managing data effectively across all stages of the data management value chain. Opinum Data Hub enables users to navigate the complexities of data, allowing them to concentrate on their core competencies. The platform primarily serves large private and public service companies, energy suppliers, and organizations with expertise in energy management.
Monolayer chemical coating technology
Opinum, based in Braine l'Alleud, Belgium, specializes in providing innovative hardware technologies and has developed the "Opinum Data Hub" platform. This platform supports energy and environmental stakeholders in their digital transformation efforts by managing data effectively across all stages of the data management value chain. Opinum Data Hub enables users to navigate the complexities of data, allowing them to concentrate on their core competencies. The platform primarily serves large private and public service companies, energy suppliers, and organizations with expertise in energy management.
Opinum, based in Braine l'Alleud, Belgium, specializes in providing innovative hardware technologies and has developed the "Opinum Data Hub" platform. This platform supports energy and environmental stakeholders in their digital transformation efforts by managing data effectively across all stages of the data management value chain. Opinum Data Hub enables users to navigate the complexities of data, allowing them to concentrate on their core competencies. The platform primarily serves large private and public service companies, energy suppliers, and organizations with expertise in energy management.
Calyos SA specializes in the development, manufacturing, and commercialization of two-phase thermal management and cooling systems. The company offers its products for high power semiconductors, such as IGBT power modules and electronic components; and electrical engines cooling and energy storage applications. Calyos SA was founded in 2011 and is based in Jumet, Belgium.